Lonza agrees to buy five US drug manufacturing sites from Merck KGaA

what happened

Swiss contract drugmaker Lonza has struck a deal to take over five American contract manufacturing facilities from Germany's Merck KGaA, according to Dow Jones Newswires. The price was not disclosed, but the company said the valuation, including debt, falls in a range of low to mid hundreds of millions of Swiss francs.

Once the deal is done, Lonza's US footprint will grow from four sites to nine. The company says the assets add manufacturing capacity in growth areas. The transaction is expected to close in mid-2027, subject to standard conditions. Lonza reaffirmed its guidance for this year and its medium-term targets.

why it matters

The United States is the world's biggest medicines market, so a larger American footprint matters strategically for Lonza. Because the deal size is moderate and guidance was left unchanged, it looks more like a company-specific move than a signal for the wider sector.

market impact

Lonza: US capacity expansion with guidance unchanged, modest impact on the shares

tags

instruments